(Calgary, Alberta, October 21, 2013) – Zephyr Sleep Technologies Inc. (Zephyr) is pleased to announce its new partnership with Respiratory Homecare Solutions (RHS) to exclusively market Zephyr’s full product line in Canada starting with our revolutionary new product, MATRx.

MATRx, is a leading edge, highly accurate medical product that brings sleep physicians and sleep dentists together to unlock the potential of oral appliance therapy. With MATRx, therapeutic outcomes are reached for obstructive sleep apnea (OSA) patients that have previously been unattainable. MATRx is an FDA cleared product and is currently installed in over 50 sleep sites in the United States and will soon be available in Canada. Zephyr and RHS are planning the Canadian product release of MATRx targeting hospitals and private sleep clinics. RHS has an experienced and knowledgeable national sales force, making their organization the ideal partner to launch MATRx in Canada.

“RHS is a proud supporter of innovation and technological advances. Our mission is to exceed expectations and the MATRx product and exciting Zephyr product pipeline fit perfectly with RHS’s determination to make a difference in the markets we serve. We will be tireless partners, promoting services that meet the needs of physicians, dentists, and most importantly the patients, who will receive better therapy as a result of these medical advances” says Rodney Rousseau, RHS’s Co-President.

“We are pleased to finally market MATRx in Canada with our partners at RHS. This partnership reflects Zephyr’s ability to build multiple paths to market in various geographies. We remain committed to innovation in the field of sleep medicine and look to RHS to help bring our other technologies and products to market in Canada in the future” says Paul Cataford, Zephyr’s President and CEO.


MATRx is a dental titration device used during polysomnography (PSG) that confirms whether an OSA patient will be successfully treated with an oral appliance. The MATRx test also provides the target protrusive position allowing for efficient and effective oral appliance therapy. “The MATRx system changes the way oral appliance therapy is prescribed, bringing the knowledge and expertise of both sleep physicians and dentists into the therapy decision much earlier. This new technology will change how sleep medicine is practiced in Canada,” says Mr. Cataford.

Oral appliance therapy has emerged as an effective alternative to continuous positive airway pressure (CPAP) in treating OSA. Studies show that patients prefer oral appliance therapy to CPAP, however only 60% respond to this alternative treatment. Until recently, there was no standard or effective prescriptive method to determine a patient’s suitability of oral appliance therapy. The introduction of MATRx technology opens a new avenue for managing OSA and changes how this disease will be treated in the future.

“Understanding a patient’s airway response to mandibular protrusion is a critical component of confidently prescribing and delivering efficacious oral appliance therapy. For our Canadian patients, MATRx means we now have a tool that allows us to confidently prescribe oral appliance therapy and eliminate the risk of patient out-of-pocket expense” states Dr. John Remmers, Zephyr’s Chief Medical Officer.

“MATRx is a proprietary and revolutionary technology that increases the quality of care, lowers overall cost of treatment and reduces treatment time. Everyone wins – the sleep physician can confidently prescribe an alternative to CPAP, the sleep dentist can now provide therapy without guesswork and the patient is treated faster and more effectively” says Dr. Shouresh Charkhandeh, Zephyr’s Chief Dental Officer.

In March of 2012, Zephyr received clearance from the U.S. Food and Drug Administration (FDA) and has since made the MATRx medical device system available in the United States. The new partnership with RHS will now allow Zephyr to have authorized sales representatives and customer support teams located throughout Canada who can provide information about Zephyr products.


Zephyr Sleep Technologies is a privately held medical device company that develops, manufactures and sells innovative, scientifically-validated medical devices to improve sleep. Zephyr works with sleep labs, technicians, physicians, dentists & leading edge sleep researchers to improve the treatment for obstructive sleep apnea. MATRx was developed by Zephyr and is based on and powered by the proprietary and patented technology known as OATRx. Zephyr is based in Calgary, Alberta. Please visit zephyrsleep.com.


Respiratory Homecare Solutions is a privately held medical services company that designs and integrates efficient, comprehensive programs, products and services for the cardio-respiratory community. Our success is measured by the satisfaction of those with whom we partner, those we employ and those we have the privilege to serve. Please visit www.rhscanada.com.


Canadian Sales
Rodney Rousseau, RRT, RPSGT, RST Co-President, Respiratory Homecare Solutions

U.S. Sales and Marketing
Mark Durston
Director of Sales and Distribution, Zephyr Sleep Technologies

RHS Marketing
Greg Stirrett
Vice President of Sales and Marketing, Respiratory Homecare Solutions


Related Articles

Image MATRx End of Life Notice

Dear valued MATRx customer, The MATRx in-lab was cleared by the Food and Drug Administration (FDA) in March, 2012 and was released in the ...

Read more